On July 9, 2026, the FDA announced a public meeting titled Drug Repurposing: Considerations for Selection Criteria and Prioritization, to be held on August 5, 2026, from 10:30 a.m. to 5:00 p.m. ET. The hybrid event, hosted by the Reagan-Udall Foundation for the FDA at its Washington, D.C. rooftop space and accessible via webcast, will review comments received in response to a recent Request for Information. It will also examine how to select and prioritize FDA-approved drugs with potential new uses. According to the agency, participants will include representatives from federal agencies, clinicians, researchers, and patient organizations. Those seeking to provide public comments must register and submit requests by 11:59 p.m. ET on July 21, 2026. Discussion topics range from examples of successful prioritization models to criteria such as unmet medical need and public health impact, along with barriers that have slowed repurposing progress.
Though described as a public forum, the meeting’s scope points to a more structured federal interest in repurposing as a policy lever. The FDA’s focus on “selection” and “prioritization” language hints at groundwork for possible frameworks that could help identify higher-value repurposing targets. Such frameworks may eventually shape NIH translational programs or influence private-sector lifecycle planning. For manufacturers, this could introduce clearer regulatory signals around the evidence needed for new indications derived from existing safety data. And for public funders and payers, a formal approach could guide investment more efficiently toward therapies addressing unmet need, without repeating early-stage research cost.
The most likely intent is to build a shared inventory of repurposing opportunities rooted in unmet need and disease burden rather than traditional market drivers. If these criteria become formalized, payers and PBMs could face an uptick in label expansions for legacy molecules entering already crowded categories. That in turn might compress reimbursement dynamics. Stakeholders are therefore watching whether this meeting sets the stage for an ongoing prioritization process or stays an exploratory policy conversation. For clinical reference on repurposed therapies, see ClinicalRx.ai.
